廣告
香港股市 將在 5 小時 29 分鐘 開市

  • 恒指

    18,313.86
    -165.51 (-0.90%)
     

  • 國指

    6,456.72
    -69.95 (-1.07%)
     

  • 上證綜指

    3,128.48
    -19.26 (-0.61%)
     

  • 道指

    39,055.53
    +171.27 (+0.44%)
     

  • 標普 500

    5,187.69
    -0.01 (-0.00%)
     

  • 納指

    16,302.76
    -29.80 (-0.18%)
     

  • Vix指數

    12.96
    -0.27 (-2.04%)
     

  • 富時100

    8,354.05
    +40.38 (+0.49%)
     

  • 紐約期油

    79.18
    +0.80 (+1.02%)
     

  • 金價

    2,316.60
    -7.60 (-0.33%)
     

  • 美元

    7.8164
    -0.0043 (-0.06%)
     

  • 人民幣

    0.9237
    +0.0013 (+0.14%)
     

  • 日圓

    0.0500
    -0.0004 (-0.70%)
     

  • 歐元

    8.3986
    -0.0127 (-0.15%)
     

  • Bitcoin

    62,154.32
    -886.44 (-1.41%)
     

  • CMC Crypto 200

    1,323.28
    +28.61 (+2.21%)
     

Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results

Vandana Singh
·1 分鐘文章

Editor's note: The headline of this story has been updated to more accurately reflect the results of the Cassava Sciences Phase 2 trial for simufilam. 

  • Cassava Sciences Inc (NASDAQ: SAVA) announced topline Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia.

  • Study participants were administered open-label simufilam tablets 100mg twice daily for one year or more. Endpoints were measured at baseline (study entry) and month 12.

  • In the mild sub-group, ADAS-Cog (cognitive scale) scores improved, from 15.0 (±6.3) to 12.6 (±7.8)

  • In the moderate sub-group, ADAS-Cog scores worsened, from 25.7 (±9.2) to 30.1 (±13.1). Investors are probably reacting to this.

  • MMSE scores (cognitive impairment) changed from 21.5 (±3.6) - 20.2 (±6.4).

  • NPI10 scores (symptom Severity and Distress score) changed from 3.2 (±4.6) to 2.9 (±4.6).

  • Simufilam 100 mg twice daily was safe and well-tolerated. There were no drug-related serious adverse events.

  • CSF biomarkers of disease pathology, t-tau, and p-tau181, decreased by 38% and 18%, respectively. CSF biomarkers of neurodegeneration, neurogranin, and neurofilament light chain decreased by 72% and 55%, respectively.

  • CSF biomarkers of neuroinflammation, sTREM2, and YKL-40, decreased by 65% and 44%.

  • Cassava Sciences is evaluating simufilam tablets for Alzheimer's disease dementia in two Phase 3 studies.

  • Most recently, FDA struck off  Eli Lilly And Co's (NYSE: LLY) donanemab for early symptomatic Alzheimer's disease due to the limited number of patients. The agency asked for additional data.

  • Price Action: SAVA shares are down 19.10% at $29.48 on the last check Tuesday.

 

廣告

 

 

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.